Journal of Inherited Metabolic Disease

, Volume 35, Issue 5, pp 837–845 | Cite as

36 months observational clinical study of 38 adult Pompe disease patients under alglucosidase alfa enzyme replacement therapy

  • Caroline Regnery
  • Cornelia Kornblum
  • Frank Hanisch
  • Stefan Vielhaber
  • Nicola Strigl-Pill
  • Birgit Grunert
  • Wolfgang Müller-Felber
  • Franz Xaver Glocker
  • Matthias Spranger
  • Marcus Deschauer
  • Eugen Mengel
  • Benedikt Schoser
Original Article



Glycogen storage disease type 2(GSD2)/Pompe disease is characterized by respiratory and skeletal muscle weakness and atrophy, resulting in functional disability and reduced life span.


We present an open-label, investigator-initiated observational study of alglucosidase alfa enzyme replacement therapy (ERT) in 38 adult-onset GSD2 patients (20 female, 18 male) with a mean age at disease onset of 36.2 ± 10.5 years. Mean delay between symptom onset and start of ERT was 14.5 ± 7.2 years. Assessments included serial Walton Gardner Medwin scale, arm function tests, timed 10-meter walk tests, 4-stair climb tests, modified Gowers’ maneuvers, 6-minute walk test (6MWT), MRC sum score, forced vital capacities (FVC), creatine kinase (CK) levels, and SF-36 self-reporting questionnaires. All tests were performed at baseline and every 12 months for 36 months of ERT.


In the 6MWT we found 21 patients able to walk at baseline a mean distance of 312 ± 165.5 m, improving to 344 ± 165.8 m after 12 months (p = 0.006), remaining at 356.4 ± 155.9 m at 24 months (p = 0.033), and declining to 325.6 ± 174.8 m after 36 months of ERT (p = 0.49, n.s.). The mean FVC in 28 patients was 80.27 ± 14.08% of predicted normal at baseline, after 12 months 79.19 ± 13.09%, at 24 months 78.62 ± 16.55%, and 77.19 ± 18.05% after 36 months. Only mean CK levels were significantly decreased by 8.8% (p = 0.041). All other tests were statistically non-significant changed.


Our data denote a rather variable course of neuromuscular deficits in chronic adult-onset Pompe patients during 36 months of alglucosidase alfa ERT.


Forced Vital Capacity Enzyme Replacement Therapy Creatine Kinase Level Pompe Disease Pompe Patient 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.



We thank the patients and their families for their patience and long-term cooperation. We also thank the technical team at the involved treatment centers. Research conducted in MC Johannes-Gutenberg-University, Mainz, Germany was supported by the European Union, 7th Framework Programme ‘EUCLYD- A European Consortium for Lysosomal Storage Diseases’ [health F2/2008 grant agreement 201678 to EM].

Competing interest

M. Deschauer, C. Kornblum, E. Mengel, W. Müller-Felber, M. Spranger, B. Schoser, S. Vielhaber have received lecturer honoraria from Genzyme Corporation.


  1. Angelini C, Semplicini C, Ravaglia S, et al. The Italian GSDII Group. (2011) Observational clinical study in juvenile-adult glycogenosis type 2 patients undergoing enzyme replacement therapy for up to 4 years. J Neurol. PMID:22081099Google Scholar
  2. Ausems MG, Wokke JH, Reuser AJ, van Diggelen OP (2001) Juvenile and adult-onset acid maltase deficiency in France: genotype-phenotype correlation. Neurology 57(10):1938PubMedCrossRefGoogle Scholar
  3. Bali DS, Tolun AA, Goldstein JL, Dai J, Kishnani PS (2011) Molecular analysis and protein processing in late-onset Pompe disease patients with low levels of acid alpha-glucosidase activity. Muscle Nerve 43(5):665–670PubMedCrossRefGoogle Scholar
  4. Banati M, Hosszu Z, Trauninger A, Szereday L, Illes Z (2011) Enzyme replacement therapy induces T-cell responses in late-onset POMPE disease. Muscle Nerve 44:720–726PubMedCrossRefGoogle Scholar
  5. Banugaria SG, Prater NA, Ng YK et al (2011) The impact of antibodies on clinical outcomes in diseases treated with therapeutic protein: Lessons learned from infantile Pompe disease. Genet Med 13:729–736PubMedCentralPubMedCrossRefGoogle Scholar
  6. Bembi B, Pisa FE, Confalonieri M et al (2010) Long-term observational, non-randomized study of enzyme replacement therapy in late-onset glycogenosis type II. J Inherit Metab Dis 33:727–735PubMedCrossRefGoogle Scholar
  7. Case LE, Koeberl DD, Young SP et al (2008) Improvement with ongoing Enzyme Replacement Therapy in advanced late-onset Pompe disease: a case study. Mol Genet Metab 95:233–235PubMedCrossRefGoogle Scholar
  8. DeRuisseau LR, Fuller DD, Qiu K et al (2009) Neural deficits contribute to respiratory insufficiency in Pompe disease. Proc Natl Acad Sci U S A 106(23):9419–9424PubMedCentralPubMedCrossRefGoogle Scholar
  9. de Vries JM, van der Beek NAME, Kroos MA et al (2010) High antibody titer in an adult with Pompe disease affects treatment with alglucosidase alfa. Mol Genet Metab 101:338–345PubMedCrossRefGoogle Scholar
  10. Fukuda T, Ewan L, Bauer M et al (2006) Dysfunction of endocytic and autophagic pathways in a lysosomal storage disease. Ann Neurol 59(4):700–708PubMedCrossRefGoogle Scholar
  11. Furusawa Y, Mori-Yoshimura M, Yamamoto T, et al (2011) Effects of enzyme replacment therapy on five patients with advanced late-onset glycogen storage disease type II : a 2- year follow-up study. J Inherit Metab Dis PMID: 21984055Google Scholar
  12. Hermans MM, van Leenen D, Kroos MA et al (2004) Twenty-two novel mutations in the lysosomal alpha-glucosidase gene (GAA) underscore the genotype-phenotype correlation in glycogen storage disease type II. Hum Mutat 23(1):47–56PubMedCrossRefGoogle Scholar
  13. Joshi PR, Glaser D, Schmidt S et al (2008) Molecular diagnosis of German patients with late-onset glycogen storage disease type II. J Inherit Metab Dis 2(Suppl):261–265CrossRefGoogle Scholar
  14. Kroos MA, Pomponio RJ, Hagemans ML et al (2007) Broad spectrum of Pompe disease in patients with the same c.-32-13T->G haplotype. Neurology 68(2):110–115PubMedCrossRefGoogle Scholar
  15. Kroos M, Pomponio RJ, van Vliet L et al (2008) Update of the Pompe disease mutation database with 107 sequence variants and a format for severity rating. Hum Mutat 29(6):E13–26PubMedCrossRefGoogle Scholar
  16. Laforet P, Nicolino M, Eymard PB et al (2000) Juvenile and adult-onset acid maltase deficiency in France: genotype-phenotype correlation. Neurology 55(8):1122–1128PubMedCrossRefGoogle Scholar
  17. Müller-Felber W, Horvath R, Gempel K et al (2007) Late onset Pompe disease: clinical and neurophysiological spectrum of 38 patients including long-term follow-up in 18 patients. Neuromuscul Disord 17:698–706PubMedCrossRefGoogle Scholar
  18. Raben N, Roberts A, Plotz PH (2007) Role of autophagy in the pathogenesis of Pompe disease. Acta Myol 26(1):45–48PubMedCentralPubMedGoogle Scholar
  19. Raben N, Ralston E, Chien YH et al (2010a) Differences in the predominance of lysosomal and autophagic pathologies between infants and adults with Pompe disease: implications for therapy. Mol Genet Metab 101(4):324–331PubMedCentralPubMedCrossRefGoogle Scholar
  20. Raben N, Schreiner C, Baum R et al (2010b) Suppression of autophagy permits successful enzyme replacement therapy in a lysosomal storage disorder–murine Pompe disease. Autophagy 6(8):1078–1089PubMedCentralPubMedCrossRefGoogle Scholar
  21. Roberts M, Kishnani PS, van der Ploeg AT et al (2011) The Impact of Scoliosis in individuals with Pompe disease: lessons learned from the Pompe registry. Mol Genet Metab 104(4):574–582PubMedCrossRefGoogle Scholar
  22. Schoser B, Muller-Hocker J, Horvath R et al (2007) Adult-onset glycogen storage disease type 2: clinico-pathological phenotype revisited. Neuropathol Appl Neurobiol 33(5):544–559PubMedGoogle Scholar
  23. Schoser B, Hill V, Raben N (2008) Therapeutic approaches in glycogen storage disease type II/Pompe disease. Neurotherapeutics 5:569–578PubMedCentralPubMedCrossRefGoogle Scholar
  24. Schüller A, Wenninger S, Strigl-Pill N, Schoser B (2012) Towards deconstructing the phenotype of late-onset Pompe disease. Am J Med Genet C doi: 10.1002/ajmg.c.31322. Google Scholar
  25. Strothotte S, Strigl-Pill N, Grunert B et al (2010) Enzyme replacement therapy with alglucosidase alfa in 44 patients with late-onset glycogen storage disease type 2: 12- month results of an observational clinical trial. J Neurol 257:91–97PubMedCrossRefGoogle Scholar
  26. Swash M, Schwartz MS, Apps MC (1985) Adult onset acid maltase deficiency. Distribution and progression of clinical and pathological abnormality in a family. J Neurol Sci 68:61–74PubMedCrossRefGoogle Scholar
  27. Van Capelle CI, Winkel LP, Hagemans ML et al (2008) Eight years experience with enzyme replacement therapy in two children and one adult with Pompe disease. Neuromuscul Disord 18:447–452PubMedCrossRefGoogle Scholar
  28. Van Capelle CI, van der Beek NA, Hagemans ML et al (2010) Effect of enzyme therapy in juvenile patients with Pompe disease: a three-year open-label study. Neuromuscul Disord 20:775–782PubMedCrossRefGoogle Scholar
  29. Van der Beek NA, Hagemans ML, Reuser AJ, Hop WC, Van der Ploeg AT, Van Doorn PA, Wokke JH (2009) Rate of disease progression during long-term follow-up of patients with late-onset Pompe disease. Neuromuscul Disord 19:113–117PubMedCrossRefGoogle Scholar
  30. Van der Beek NA, van Capelle CI, van der Velden KI et al (2011) Rate of progression and predictive factors for pulmonary outcome in children and adults with Pompe disease. Mol Genet Metab 104:129–136PubMedCrossRefGoogle Scholar
  31. Van der Ploeg AT, Reuser AJ (2008) Pompe’s disease. Lancet 372:1342–1353PubMedCrossRefGoogle Scholar
  32. Van der Ploeg AT, Clemens PR, Corzo D et al (2010) A randomized study of alglucosidase alfa in late- onset Pompe’s disease. N Engl J Med 362:1396–1406PubMedCrossRefGoogle Scholar
  33. Vielhaber S, Brejova A, Debska-Vielhaber G et al (2011) 24-months results in two adults with Pompe disease on enzyme replacement therapy. Clin Neurol Neurosurg 113:350–357PubMedCrossRefGoogle Scholar
  34. Winkel LP, Hagemans ML, van Doorn PA et al (2005) The natural course of non-classic Pompe’s disease; a review of 225 published cases. J Neurol 252:875–884PubMedCrossRefGoogle Scholar
  35. Yang CC, Chien YH, Lee NC et al (2011) Rapid progressive course of later-onset Pompe disease in Chinese patients. Mol Genet Metab 104(3):284–288PubMedCrossRefGoogle Scholar

Copyright information

© SSIEM and Springer 2012

Authors and Affiliations

  • Caroline Regnery
    • 1
  • Cornelia Kornblum
    • 2
  • Frank Hanisch
    • 3
  • Stefan Vielhaber
    • 4
  • Nicola Strigl-Pill
    • 1
  • Birgit Grunert
    • 5
  • Wolfgang Müller-Felber
    • 1
    • 6
  • Franz Xaver Glocker
    • 7
  • Matthias Spranger
    • 5
  • Marcus Deschauer
    • 3
  • Eugen Mengel
    • 8
  • Benedikt Schoser
    • 1
  1. 1.Friedrich-Baur Institute, Department of NeurologyLudwig-Maximilians University MunichMunichGermany
  2. 2.Department of NeurologyUniversity Hospital of BonnBonnGermany
  3. 3.Department of NeurologyMartin-Luther-University Halle-WittenbergHalleGermany
  4. 4.Department of NeurologyUniversity Hospital MagdeburgMagdeburgGermany
  5. 5.Neurologisches Rehabilitationszentrum FriedehorstBremenGermany
  6. 6.Department of NeuropaediatricsLudwig-Maximilians University MunichMunichGermany
  7. 7.Department of NeurologyUniversity Hospital FreiburgFreiburgGermany
  8. 8.Department of PaediatricsJohannes-Gutenberg University MainzMainzGermany

Personalised recommendations